Neurological7 residues

Selank

Tuftsin analogue

Selank is a synthetic peptide related to tuftsin. The primary study discussed here examines neurotransmission-related gene expression in rats, not clinical outcomes in a general population.

Reviewed September 2026

Residues
7. calculated: Count of residues in the stored canonical reference sequence; terminal groups are not extra residues.
Average mass
751.87 Da. calculated: Calculated average neutral molecular mass of the unmodified free-terminal sequence, including one terminal water. Not monoisotopic mass; salts, counterions and solvates excluded.
pI
11.00 (theoretical). calculated: Theoretical Bjellqvist/Biopython charge-model pI for the stated free-terminal, unmodified sequence (pH search 0–14). Model-dependent, not measured pI or formulation pH; not applicable to an unspecified amidated, acetylated or salt preparation.

Primary structure

Sequence

N-terminusC-terminus
ThreonineThr · TOpen amino-acid reference

Peptide. Sequence describes the reference peptide, not a tested supplier lot.

Calculated properties

Calculated from the sequence
FormulaC33H57N11O9
Monoisotopic mass751.4341 Da
Extinction coefficient at 280 nmNone (no Tyr or Trp)
A280 at 1 mg/mLNot measurable
Residues7
Average mass751.87 Da
pI11.00 (theoretical)
Identity
AliasesTuftsin analogue
SequenceTKPRPGP
Research areaNeurological

Property basis and sources

These describe the reference compound or formulation, not identification or testing of the supplied lot.

Calculation scope: the stored canonical amino-acid sequence with free N- and C-termini, no other modifications or counterions. This specifies a reference form, not the chemical form or identity of a sold lot.

  • Residues: 7 (calculated). Count of residues in the stored canonical reference sequence; terminal groups are not extra residues. Residues source 1
  • Average mass: 751.87 Da (calculated). Calculated average neutral molecular mass of the unmodified free-terminal sequence, including one terminal water. Not monoisotopic mass; salts, counterions and solvates excluded. Average mass source 1 Average mass source 2 Average mass source 3
  • pI: 11.00 (theoretical) (calculated). Theoretical Bjellqvist/Biopython charge-model pI for the stated free-terminal, unmodified sequence (pH search 0–14). Model-dependent, not measured pI or formulation pH; not applicable to an unspecified amidated, acetylated or salt preparation. pI source 1 pI source 2

Residue composition

Unique residues
5
Most common
Proline
Nonpolar residues
0
Other classified residues
7

Proline is the most common residue (3). The calculated charge at pH 7 is net positive (1.99).

Reference scope and linked records

Reference type: Peptide.

This is a research-reference entry, not a product certificate, treatment recommendation or administration guide. The sources below describe their own materials and methods. Catalogue identity, lot testing and clinical evidence are separate questions.

Catalogue context: Selank. The product retains its own name and specification; this link does not certify equivalence to published study material.

Related references

Sources and their scope

  1. Selank administration and genes involved in GABAergic neurotransmission. Source for the chemistry or study context discussed above; not an Aminos lot certificate.

Source check: 26 September 2026. This is an editorial source check, not a claim of independent clinical or laboratory review.

About Selank

Identity and context

The reported sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro. It is different from Semax, despite both names appearing in neurological research catalogues. Comparisons should retain the complete identity rather than treating the two as alternative spellings or formulations.

Reference classification

Peptide. The linked catalogue product is Selank. This reference does not independently authenticate the material supplied.

Storage and handling

Analytical specification

Check the full sequence, terminal groups and analytical identity. Do not transfer stability, pharmacology or clinical claims from Semax to Selank simply because both are short peptides.

Storage and experimental handling

Use the documented conditions for the actual chemical form and preparation. No universal storage temperature, expiry or solution shelf life is assigned here. Follow the lot documentation, safety data sheet and validated laboratory protocol; this page is not a reconstitution or administration guide.

Research evidence

Research evidence for this compound
AreaSummaryEvidence
What the source examinesVolkova and colleagues assessed gene expression in rat frontal cortex after Selank or GABA administration. They found time-dependent changes in a panel of neurotransmission-related genes and proposed involvement of the GABAergic system. Gene expression provides a mechanistic observation, not a direct measurement of anxiety relief in humans.Source context
What cannot be inferredThis study does not establish that Selank acts exactly like a benzodiazepine, is free of adverse effects or has a proven benefit in the person reading this page. No regulatory status is inferred from the originating country of a paper.Evidence limits

References

Sources used for the data on this page, checked September 2026.

  1. Selank administration and genes involved in GABAergic neurotransmissionPrimary source for the reference discussion; not lot-specific product evidence.

Reference information only. This page describes the chemistry and published research context of a laboratory compound. Nothing here is medical or dosing advice. Aminos compounds are for laboratory research use only and are not medicines.